Ipsen (IPSEY) and Foreseen Biotechnology have established an exclusive global licensing agreement for FS001, an innovative antibody-drug conjugate (ADC) with first-in-class potential.
FS001 targets a novel tumor-associated antigen that is highly expressed across various solid tumors. This antigen was identified through Foreseen's proprietary proteomic platforms.
According to the companies, FS001 has shown significant preclinical efficacy in multiple tumor models and maintains a favorable preclinical safety profile.
Foreseen Biotechnology is eligible to receive up to $1.03 billion, including upfront payments, and developmental, regulatory, and commercial milestone payments. They will also receive tiered royalties on global sales, subject to successful development and regulatory approvals.
Under the agreement, Ipsen will be responsible for Phase I preparation activities, including the submission of the Investigational New Drug (IND) application, and will handle all subsequent clinical development, manufacturing, and global commercialization activities.
